Loading
Extracellular Vesicles in Disease · Journal article
International Journal of Current Science Research and Review · August 10, 2026
A consensus or society position rather than new primary data.
This is a narrative systematic review synthesizing evidence on exosome isolation methods and their proposed role in cancer therapy. It identifies exosomes as promising intercellular carriers with potential for drug delivery and gene therapy, but does not report primary efficacy data or comparative clinical outcomes.
Systematic narrative review. Published scientific literature; not a clinical cohort study.. Intervention: Exosome isolation methods (microfluidics, spectroscopy) and exosome-based cancer therapy approaches, including CRISPR-Cas pairing.. Compared with: Synthetic nanoparticles; conventional (non-microfluidics) isolation methods.. International databases searched; no geographic restriction specified..
Exosomes are nano-sized extracellular vehicles (30–150 nm) released via the endosomal route with potential to cross the blood-brain barrier Microfluidics-based isolation methods significantly reduce isolation time compared to conventional approaches Combination of exosomes with CRISPR-Cas systems has opened new directions for gene therapy applications
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should recognize exosomes as an emerging tool in preclinical and early translational cancer therapy development, but clinical efficacy and safety in human cancer patients remain to be established in controlled trials.
This is a systematic narrative review synthesizing literature on exosome biology, isolation methods, and cancer applications; it provides a landscape appraisal rather than original clinical evidence or a randomized trial.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should recognize exosomes as an emerging tool in preclinical and early translational cancer therapy development, but clinical efficacy and safety in human cancer patients remain to be established in controlled trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract: Exosomes are a subset of nano-sized (30–150 nm) extracellular vehicles (EVs) released by cells through the endosomal route, you know like they get made inside and then pushed out. Objective: The primary objective of this scientific review is to give a broad and current appraisal of the intricate biological layout of exosomes, plus modern isolation technologies (for instance microfluidics and spectroscopy), and finally their clinical meaning for cancer detection and treatment. Methods: This article is arranged following systematic review logic based on credible scientific sources from the last decade 2015–2025. Data collection involved international databases, including PubMed, Scopus and Web of Science. The analysis looks at how exosome biogenesis connects with drug delivery systems (DDS), and how that whole interplay affects the tumor microenvironment, using both qualitative and quantitative comparative approaches. The guidelines from the International Society for Extracellular Vesicles (ISEV) were used as a kind of standard for study rigor. Key Findings: A growing body of research suggests that exosomes work as important intercellular message carriers, meaning they are deeply involved in cancer metastasis. Their nano-sized form, the potential to move across the blood-brain barrier (BBB), and their inherent biocompatibility make them a stronger, more natural alternative in comparison with synthetic nanoparticles. Innovative methods such as microfluidics have cut the isolation time a lot, and pairing exosomes with the CRISPR-Cas system has basically opened new directions for gene therapy. In the end, the review also tackles difficulties in standardization and large-scale production, while stressing that exosome engineering is likely the upcoming step change for precision cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.